Press Releases Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
1.690 ^USD	+4.32%		+12.67%	+25.19%

06/11	Ocugen, Inc., Q3 2025 Earnings Call, Nov 05, 2025
05/11	Ocugen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Press Releases

15/01	Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	GL
13/01	Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data	GL
12/01	Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference	AQ
12/01	Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy	GL
09/01	Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference	GL
10/12	Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit	GL
20/11	Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference	GL
20/11	Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference	AQ
17/11	Resetting retinal networks with a gene-agnostic approach	AQ
05/11	Ocugen: Q3 Earnings Snapshot	AQ
05/11	Ocugen Provides Business Update with Third Quarter 2025 Financial Results	GL
23/25/23	Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results	GL
02/25/02	Ocugen to Present at Industry and Investor Conferences in October 2025	GL
15/25/15	Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	GL
02/25/02	Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025	GL
13/25/13	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease	GL
13/25/13	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease	AQ
13/25/13	Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants	GL
12/25/12	Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants	AQ
09/25/09	Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants	GL
06/25/06	Eastern District Of Pennsylvania Dismisses Putative Class Action Against Biotechnology Company For Failure To Adequately Allege Materiality Or Falsity	AQ
01/25/01	Ocugen: Q2 Earnings Snapshot	AQ
01/25/01	Ocugen Provides Business Update with Second Quarter 2025 Financial Results	GL
22/25/22	Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team	AQ
21/25/21	Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Press Releases

Filters